I2O Therapeutics receives strategic investment from Colorcon Ventures

▴ I2O Therapeutics receives strategic investment from Colorcon Ventures
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts

i2O Therapeutics, an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc. In addition to this investment, Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts. i2O previously announced its seed round of financing led by Sanofi Ventures and JDRF T1D Fund in April 2020.

“We welcome Colorcon Ventures as a strategic investor at this pivotal time of company growth,” said Ravi Srinivasan, Ph.D., Chief Executive Officer of i2O Therapeutics.

Founded by a team of researchers from Harvard University, i2O Therapeutics is focused on the development of safe and effective oral formulations of therapies that are conventionally limited to injections, e.g. biologics, large molecules, and peptide-based pharmaceuticals such as insulin. The company’s innovative platform enables drugs that traditionally would not survive the hostile environment of the digestive system to pass through safely by utilizing a unique coating that dissolves in the small intestine, thereby releasing the active drug. i2O’s initial focus is on developing a novel oral formulation for GLP-1 analogs.

“We are excited to collaborate with Colorcon to help advance our ionic liquid technology given their rich history of innovation and expertise in pharmaceutical development,” said Samir Mitragotri, Ph.D., Co-founder of i2O Therapeutics.

“Colorcon Ventures’ strategic focus on technologies that transform conventional delivery pathways aligns well with i2O. The ability to deliver injectable therapies orally has the potential to significantly improve patient adherence and outcomes,” commented Martti Hedman, Colorcon’s Chief Executive Officer.

Dr Ali Rajabi-Siahboomi, Chief Scientific Officer of Colorcon states, “Colorcon's excipients and in-depth pharmaceutical development expertise will help advance the use of ionic liquids for the oral delivery of challenging molecules.”

Tags : #i20Therapeutics #LatestNewsini20Therapeutics4thDec #LatestPharmaNews4thDec #ColorconVentures #HarvardUniversity

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Empowering Consumers with Nutritional Information: FSSAI's New Labeling GuidelinesJuly 12, 2024
Innovative Migraine Research Uncovers Key Triggers and Pathways for PainJuly 12, 2024
Alarming Rise in Death's Due to HIV Among Students in Tripura: Urgent Need for ActionJuly 12, 2024
Amrita Vishwa Vidyapeetham is All Set to Produce Netravaad, an Innovative Technology for Speech Impairment July 11, 2024
Twice-Yearly Injection Shows 100% HIV Protection in Young WomenJuly 11, 2024
AIMS (Asian Hospital) Doctors Restore Disfigured Face of Road Accident VictimJuly 10, 2024
Will #PutPeopleFirst mantra drive HIV responses?July 10, 2024
Shiprocket and Snowflake AI Data Cloud to empower 1.5 lakh merchants of BHARAT to scale their data infrastructureJuly 10, 2024
Dr. Shilpa Vora, Marico expert shares tips on how you can safeguard your baby’s skin during the monsoon seasonJuly 10, 2024
Pre Budget 2024 (Ms. Deepshikha Sharma- CEO of Sharp Sight Eye Hospital) July 10, 2024
Rate of global warming caused by humans at an all-time high - research led by University of LeedsJuly 09, 2024
Dengue during Monsoon Season and Neurological Complications Associated with DengueJuly 09, 2024
Yodda Elder Care Renews Partnership with Medulance for Emergency ServicesJuly 09, 2024
Budget Expectation Quote- Dr. Sanjeev Singh, Medical Director, Amrita Hospital, FaridabadJuly 08, 2024
Honourable Justice R. Mahadevan, Chief Justice of Madras High Court, Chennai Inaugurates IIRSI 2024, India's Premier Convention on Eye SurgeryJuly 06, 2024
The Impact of Architecture on Academic Performance: How Exam Hall Design Affects Student SuccessJuly 06, 2024
Teen Dies from Brain-Eating Amoeba in Kerala: Fatal Naegleria fowleri Infections SurgeJuly 05, 2024
Chemotherapy Drug Linked to Long-Term Hearing Loss in Cancer SurvivorsJuly 05, 2024
Qatar Airways Chooses Çelebi India as Ground Handler for New Doha-Goa FlightsJuly 04, 2024
Zika Virus Alert in Maharashtra: Government's Proactive Steps for Public SafetyJuly 04, 2024